Listed

Cryo Cell International Inc

CCELNYSECIK 862692HealthcareFiscal year ends Nov 30

Latest reported revenue, Q3 FY2026$7.8mRevenue, Q3 FY2026, three months to 2026-08-31$7.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-10-09, accession 0001193125-26-419156.Report this figureThree months to Aug 31, 2026, from the 10-Q filed Oct 9, 2026.

Latest quarter: Q3 FY2026

Three months to Aug 31, 2026, against the same quarter a year earlier.

  • Revenue$7.8mRevenue, Q3 FY2026, three months to 2026-08-31$7.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-10-09, accession 0001193125-26-419156.Report this figure−0.0% on a year earlier
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating margin28.0%Operating margin, Q3 FY2026, three months to 2026-08-31. operating income / revenueOperating income: $2.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-10-09, accession 0001193125-26-419156.Revenue: $7.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-10-09, accession 0001193125-26-419156.Report this figure+3.8 pts on a year earlier
  • Net margin16.2%Net margin, Q3 FY2026, three months to 2026-08-31. net income / revenueNet income: $1.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-09, accession 0001193125-26-419156.Revenue: $7.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-10-09, accession 0001193125-26-419156.Report this figure+6.7 pts on a year earlier
  • Diluted EPS$0.16Diluted EPS, Q3 FY2026, three months to 2026-08-31$0.16 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-10-09, accession 0001193125-26-419156.Report this figure+77.8% on a year earlier
  • Free cash flow$1.0mFree cash flow, Q3 FY2026, three months to 2026-08-31. operating cash flow − capital expenditureOperating cash flow: $1.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-10-09, accession 0001193125-26-419156. Derived: 9-month figure less the 6-month figure.Capital expenditure: $101.9k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-10-09, accession 0001193125-26-419156. Derived: 9-month figure less the 6-month figure.Report this figure−58.4% on a year earlier

Last eight quarters

Full statements
Revenue$7.8mOperating margin 28.0%
Diluted EPS$0.16, Q3 FY2026
Free cash flow$1.0m, Q3 FY2026
Cryo Cell International Inc, key figures for the last eight quarters
Line itemUnitQ4 FY20242024-11-30Q1 FY20252025-02-28Q2 FY20252025-05-31Q3 FY20252025-08-31Q4 FY20252025-11-30Q1 FY20262026-02-28Q2 FY20262026-05-31Q3 FY20262026-08-31Shape over the periods
Revenue$k8,024Revenue, Q4 FY2024, three months to 2024-11-30$8.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-27, accession 0001193125-26-083096. Derived: 12-month figure less the 9-month figure.Report this figure7,969Revenue, Q1 FY2025, three months to 2025-02-28$8.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-04-14, accession 0001193125-26-155057.Report this figure7,929Revenue, Q2 FY2025, three months to 2025-05-31$7.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-07-15, accession 0001193125-26-304834.Report this figure7,825Revenue, Q3 FY2025, three months to 2025-08-31$7.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-10-09, accession 0001193125-26-419156.Report this figure7,843Revenue, Q4 FY2025, three months to 2025-11-30$7.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-27, accession 0001193125-26-083096. Derived: 12-month figure less the 9-month figure.Report this figure7,683Revenue, Q1 FY2026, three months to 2026-02-28$7.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-04-14, accession 0001193125-26-155057.Report this figure7,776Revenue, Q2 FY2026, three months to 2026-05-31$7.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-07-15, accession 0001193125-26-304834.Report this figure7,824Revenue, Q3 FY2026, three months to 2026-08-31$7.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-10-09, accession 0001193125-26-419156.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%(1.5%)Operating margin, Q4 FY2024, three months to 2024-11-30. operating income / revenueOperating income: −$122.3k. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-27, accession 0001193125-26-083096. Derived: 12-month figure less the 9-month figure.Revenue: $8.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-27, accession 0001193125-26-083096. Derived: 12-month figure less the 9-month figure.Report this figure13.3%Operating margin, Q1 FY2025, three months to 2025-02-28. operating income / revenueOperating income: $1.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-04-14, accession 0001193125-26-155057.Revenue: $8.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-04-14, accession 0001193125-26-155057.Report this figure18.8%Operating margin, Q2 FY2025, three months to 2025-05-31. operating income / revenueOperating income: $1.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-07-15, accession 0001193125-26-304834.Revenue: $7.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-07-15, accession 0001193125-26-304834.Report this figure24.3%Operating margin, Q3 FY2025, three months to 2025-08-31. operating income / revenueOperating income: $1.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-10-09, accession 0001193125-26-419156.Revenue: $7.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-10-09, accession 0001193125-26-419156.Report this figure(50.6%)Operating margin, Q4 FY2025, three months to 2025-11-30. operating income / revenueOperating income: −$4.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-27, accession 0001193125-26-083096. Derived: 12-month figure less the 9-month figure.Revenue: $7.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-27, accession 0001193125-26-083096. Derived: 12-month figure less the 9-month figure.Report this figure10.0%Operating margin, Q1 FY2026, three months to 2026-02-28. operating income / revenueOperating income: $765.1k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-04-14, accession 0001193125-26-155057.Revenue: $7.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-04-14, accession 0001193125-26-155057.Report this figure15.4%Operating margin, Q2 FY2026, three months to 2026-05-31. operating income / revenueOperating income: $1.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-07-15, accession 0001193125-26-304834.Revenue: $7.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-07-15, accession 0001193125-26-304834.Report this figure28.0%Operating margin, Q3 FY2026, three months to 2026-08-31. operating income / revenueOperating income: $2.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-10-09, accession 0001193125-26-419156.Revenue: $7.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-10-09, accession 0001193125-26-419156.Report this figure
Net margin%(23.2%)Net margin, Q4 FY2024, three months to 2024-11-30. net income / revenueNet income: −$1.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-27, accession 0001193125-26-083096. Derived: 12-month figure less the 9-month figure.Revenue: $8.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-27, accession 0001193125-26-083096. Derived: 12-month figure less the 9-month figure.Report this figure3.5%Net margin, Q1 FY2025, three months to 2025-02-28. net income / revenueNet income: $282.9k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-04-14, accession 0001193125-26-155057.Revenue: $8.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-04-14, accession 0001193125-26-155057.Report this figure4.5%Net margin, Q2 FY2025, three months to 2025-05-31. net income / revenueNet income: $355.8k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-15, accession 0001193125-26-304834.Revenue: $7.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-07-15, accession 0001193125-26-304834.Report this figure9.6%Net margin, Q3 FY2025, three months to 2025-08-31. net income / revenueNet income: $749.4k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-09, accession 0001193125-26-419156.Revenue: $7.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-10-09, accession 0001193125-26-419156.Report this figure(48.7%)Net margin, Q4 FY2025, three months to 2025-11-30. net income / revenueNet income: −$3.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-27, accession 0001193125-26-083096. Derived: 12-month figure less the 9-month figure.Revenue: $7.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-27, accession 0001193125-26-083096. Derived: 12-month figure less the 9-month figure.Report this figure0.6%Net margin, Q1 FY2026, three months to 2026-02-28. net income / revenueNet income: $47.1k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-04-14, accession 0001193125-26-155057.Revenue: $7.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-04-14, accession 0001193125-26-155057.Report this figure7.1%Net margin, Q2 FY2026, three months to 2026-05-31. net income / revenueNet income: $554.6k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-15, accession 0001193125-26-304834.Revenue: $7.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-07-15, accession 0001193125-26-304834.Report this figure16.2%Net margin, Q3 FY2026, three months to 2026-08-31. net income / revenueNet income: $1.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-09, accession 0001193125-26-419156.Revenue: $7.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-10-09, accession 0001193125-26-419156.Report this figure
Diluted EPS$ per sharenot reported (Diluted EPS not reported)0.03Diluted EPS, Q1 FY2025, three months to 2025-02-28$0.03 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-04-14, accession 0001193125-26-155057.Report this figure0.04Diluted EPS, Q2 FY2025, three months to 2025-05-31$0.04 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-07-15, accession 0001193125-26-304834.Report this figure0.09Diluted EPS, Q3 FY2025, three months to 2025-08-31$0.09 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-10-09, accession 0001193125-26-419156.Report this figurenot reported (Diluted EPS not reported)0.01Diluted EPS, Q1 FY2026, three months to 2026-02-28$0.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-04-14, accession 0001193125-26-155057.Report this figure0.07Diluted EPS, Q2 FY2026, three months to 2026-05-31$0.07 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-07-15, accession 0001193125-26-304834.Report this figure0.16Diluted EPS, Q3 FY2026, three months to 2026-08-31$0.16 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-10-09, accession 0001193125-26-419156.Report this figure
Free cash flow$k2,149Free cash flow, Q4 FY2024, three months to 2024-11-30. operating cash flow − capital expenditureOperating cash flow: $2.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-27, accession 0001193125-26-083096. Derived: 12-month figure less the 9-month figure.Capital expenditure: $8.3k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-27, accession 0001193125-26-083096. Derived: 12-month figure less the 9-month figure.Report this figure892Free cash flow, Q1 FY2025, three months to 2025-02-28. operating cash flow − capital expenditureOperating cash flow: $954.1k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-04-14, accession 0001193125-26-155057.Capital expenditure: $62.1k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-04-14, accession 0001193125-26-155057.Report this figure645Free cash flow, Q2 FY2025, three months to 2025-05-31. operating cash flow − capital expenditureOperating cash flow: $707.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-07-15, accession 0001193125-26-304834. Derived: 6-month figure less the 3-month figure.Capital expenditure: $62.4k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-07-15, accession 0001193125-26-304834. Derived: 6-month figure less the 3-month figure.Report this figure2,498Free cash flow, Q3 FY2025, three months to 2025-08-31. operating cash flow − capital expenditureOperating cash flow: $2.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-10-09, accession 0001193125-26-419156. Derived: 9-month figure less the 6-month figure.Capital expenditure: $38.8k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-10-09, accession 0001193125-26-419156. Derived: 9-month figure less the 6-month figure.Report this figure1,214Free cash flow, Q4 FY2025, three months to 2025-11-30. operating cash flow − capital expenditureOperating cash flow: $1.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-27, accession 0001193125-26-083096. Derived: 12-month figure less the 9-month figure.Capital expenditure: $67.2k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-27, accession 0001193125-26-083096. Derived: 12-month figure less the 9-month figure.Report this figure585Free cash flow, Q1 FY2026, three months to 2026-02-28. operating cash flow − capital expenditureOperating cash flow: $651.8k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-04-14, accession 0001193125-26-155057.Capital expenditure: $67.1k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-04-14, accession 0001193125-26-155057.Report this figure1,813Free cash flow, Q2 FY2026, three months to 2026-05-31. operating cash flow − capital expenditureOperating cash flow: $1.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-07-15, accession 0001193125-26-304834. Derived: 6-month figure less the 3-month figure.Capital expenditure: $32.7k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-07-15, accession 0001193125-26-304834. Derived: 6-month figure less the 3-month figure.Report this figure1,040Free cash flow, Q3 FY2026, three months to 2026-08-31. operating cash flow − capital expenditureOperating cash flow: $1.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-10-09, accession 0001193125-26-419156. Derived: 9-month figure less the 6-month figure.Capital expenditure: $101.9k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-10-09, accession 0001193125-26-419156. Derived: 9-month figure less the 6-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$31.6mOperating margin 1.5%
Diluted EPS−$0.30, FY2025
Free cash flow$5.2m, FY2025
Cryo Cell International Inc, key figures for the last five fiscal years
Line itemUnitFY20212021-11-30FY20222022-11-30FY20232023-11-30FY20242024-11-30FY20252025-11-30Shape over the periods
Revenue$m28.9Revenue, FY2021, twelve months to 2021-11-30$28.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2023-02-28, accession 0000950170-23-005220.Report this figure30.3Revenue, FY2022, twelve months to 2022-11-30$30.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2024-02-28, accession 0000950170-24-022275.Report this figure31.3Revenue, FY2023, twelve months to 2023-11-30$31.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2025-02-28, accession 0000950170-25-030138.Report this figure32.0Revenue, FY2024, twelve months to 2024-11-30$32.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-27, accession 0001193125-26-083096.Report this figure31.6Revenue, FY2025, twelve months to 2025-11-30$31.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-27, accession 0001193125-26-083096.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%13.9%Operating margin, FY2021, twelve months to 2021-11-30. operating income / revenueOperating income: $4.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2023-02-28, accession 0000950170-23-005220.Revenue: $28.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2023-02-28, accession 0000950170-23-005220.Report this figure13.3%Operating margin, FY2022, twelve months to 2022-11-30. operating income / revenueOperating income: $4.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-02-28, accession 0000950170-24-022275.Revenue: $30.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2024-02-28, accession 0000950170-24-022275.Report this figure(39.3%)Operating margin, FY2023, twelve months to 2023-11-30. operating income / revenueOperating income: −$12.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-02-28, accession 0000950170-25-030138.Revenue: $31.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2025-02-28, accession 0000950170-25-030138.Report this figure10.9%Operating margin, FY2024, twelve months to 2024-11-30. operating income / revenueOperating income: $3.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-27, accession 0001193125-26-083096.Revenue: $32.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-27, accession 0001193125-26-083096.Report this figure1.5%Operating margin, FY2025, twelve months to 2025-11-30. operating income / revenueOperating income: $482.4k. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-27, accession 0001193125-26-083096.Revenue: $31.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-27, accession 0001193125-26-083096.Report this figure
Net margin%7.2%Net margin, FY2021, twelve months to 2021-11-30. net income / revenueNet income: $2.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2023-02-28, accession 0000950170-23-005220.Revenue: $28.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2023-02-28, accession 0000950170-23-005220.Report this figure9.1%Net margin, FY2022, twelve months to 2022-11-30. net income / revenueNet income: $2.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-02-28, accession 0000950170-24-022275.Revenue: $30.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2024-02-28, accession 0000950170-24-022275.Report this figure(30.4%)Net margin, FY2023, twelve months to 2023-11-30. net income / revenueNet income: −$9.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-02-28, accession 0000950170-25-030138.Revenue: $31.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2025-02-28, accession 0000950170-25-030138.Report this figure1.3%Net margin, FY2024, twelve months to 2024-11-30. net income / revenueNet income: $402.1k. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-27, accession 0001193125-26-083096.Revenue: $32.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-27, accession 0001193125-26-083096.Report this figure(7.7%)Net margin, FY2025, twelve months to 2025-11-30. net income / revenueNet income: −$2.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-27, accession 0001193125-26-083096.Revenue: $31.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-27, accession 0001193125-26-083096.Report this figure
Diluted EPS$ per share0.25Diluted EPS, FY2021, twelve months to 2021-11-30$0.25 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2023-02-28, accession 0000950170-23-005220.Report this figure0.33Diluted EPS, FY2022, twelve months to 2022-11-30$0.33 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-02-28, accession 0000950170-24-022275.Report this figure(1.14)Diluted EPS, FY2023, twelve months to 2023-11-30−$1.14 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-02-28, accession 0000950170-25-030138.Report this figure0.05Diluted EPS, FY2024, twelve months to 2024-11-30$0.05 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-27, accession 0001193125-26-083096.Report this figure(0.30)Diluted EPS, FY2025, twelve months to 2025-11-30−$0.30 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-27, accession 0001193125-26-083096.Report this figure
Free cash flow$m6.1Free cash flow, FY2021, twelve months to 2021-11-30. operating cash flow − capital expenditureOperating cash flow: $7.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2023-02-28, accession 0000950170-23-005220.Capital expenditure: $1.8m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2023-02-28, accession 0000950170-23-005220.Report this figure(3.6)Free cash flow, FY2022, twelve months to 2022-11-30. operating cash flow − capital expenditureOperating cash flow: $8.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-02-28, accession 0000950170-24-022275.Capital expenditure: $12.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-02-28, accession 0000950170-24-022275.Report this figure2.1Free cash flow, FY2023, twelve months to 2023-11-30. operating cash flow − capital expenditureOperating cash flow: $8.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-02-28, accession 0000950170-25-030138.Capital expenditure: $6.8m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-02-28, accession 0000950170-25-030138.Report this figure3.6Free cash flow, FY2024, twelve months to 2024-11-30. operating cash flow − capital expenditureOperating cash flow: $6.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-27, accession 0001193125-26-083096.Capital expenditure: $2.4m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-27, accession 0001193125-26-083096.Report this figure5.2Free cash flow, FY2025, twelve months to 2025-11-30. operating cash flow − capital expenditureOperating cash flow: $5.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-27, accession 0001193125-26-083096.Capital expenditure: $230.5k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-27, accession 0001193125-26-083096.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Cryo Cell International Inc
FundQuarter endedReported valueSharesPut or callChange on the quarter before
SFI Advisors, LLC2026-06-30$527.3k165,300Unchanged
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$526.3k164,976Added+3,452
MassMutual Private Wealth & Trust, FSB2026-06-30$354.2k111,035Unchanged
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$147.7k46,273Added+2,657
VANGUARD FIDUCIARY TRUST CO2026-06-30$74.5k23,346Unchanged
FMR LLC2026-06-30$63.8k20,000New+20,000
SUSQUEHANNA INTERNATIONAL GROUP, LLP2026-06-30$44.9k14,064Added+4,046
BlackRock, Inc.2026-06-30$21.4k6,696Reduced−7,287
OSAIC HOLDINGS, INC.2026-06-30$8.0k2,500Unchanged
MORGAN STANLEY2026-06-30$1.9k605Added+4

Recent filings

All 663 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Cryo Cell International Inc, recent filings
FiledFormWhat it isAccession number
2026-10-1321:00 ETDEF 14AProxy statementPeriod 2026-10-270001193125-26-420608
2026-10-0920:30 ET10-QQuarterly reportPeriod 2026-08-310001193125-26-419156
2026-09-1420:30 ET8-K8.01 Other events0001193125-26-390647
2026-07-1520:30 ET10-QQuarterly reportPeriod 2026-05-310001193125-26-304834
2026-07-0713:01 ETSCHEDULE 13D/AOwnership report, active investor, amended0001493152-26-032265
2026-05-0820:00 ET8-K3.01 Delisting notice; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001193125-26-214569
2026-04-1421:00 ET10-QQuarterly reportPeriod 2026-02-280001193125-26-155057
2026-03-2501:54 ETSCHEDULE 13DOwnership report, active investor0001493152-26-012763
2026-03-1221:00 ET8-K3.01 Delisting notice; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001193125-26-104392
2026-02-2722:01 ET10-KAnnual reportPeriod 2025-11-300001193125-26-083096

Latest annual report

Form 10-K for the fiscal year ended Nov 30, 2025Filed Feb 27, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Not in this season’s league. The league lists companies whose quarter has ended and whose results are not yet filed.This season’s league

About the filer

CIK
862692
Tickers
CCEL
Exchange
NYSE
SIC code
8090 Services-Misc Health & Allied Services, NEC
Sector
Healthcare
Fiscal year ends
Nov 30
Incorporated in
DE
Filer category
Non-accelerated filer<br>Smaller reporting company
Former names
CRYO CELL INTERNATIONAL INC (to 2026-10-13)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:26 ET. Listed shows no prices and gives no investment advice.